How can drug discovery for psychiatric disorders be improved?

Nature Reviews Drug Discovery

Volumn 6, Issue 3, 2007, Pages 189-201

  Agid, Yves ^a   Buzsáki, György ^b   Diamond, David M ^c   Frackowiak, Richard ^d   Giedd, Jay ^e   Girault, Jean Antoine ^f   Grace, Anthony ^g   Lambert, Jeremy J ^h   Manji, Husseini ^e   Mayberg, Helen ⁱ   Popoli, Maurizio ^j   Prochiantz, Alain ^k   Richter Levin, Gal ^l   Somogyi, Peter ^m   Spedding, Michael ⁿ   Svenningsson, Per ^o   Weinberger, Daniel ^e  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b RUTGERS UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^f INSTITUT DU FER À MOULIN   (France)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF DUNDEE   (United Kingdom)

ⁱ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF MILAN   (Italy)

^k ECOLE NORMALE SUPÉRIEURE   (France)

^l UNIVERSITY OF HAIFA   (Israel)

^m UNIVERSITY OF OXFORD   (United Kingdom)

ⁿ IDRS   (France)

^o KAROLINSKA INSTITUTE   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; AMPA RECEPTOR; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BRAIN DERIVED NEUROTROPHIC FACTOR; CASEIN KINASE I; CATECHOL METHYLTRANSFERASE; CYCLIN DEPENDENT KINASE 5; DEXAMPHETAMINE; DIAZEPAM; DOPAMINE RECEPTOR BLOCKING AGENT; GLYCOGEN SYNTHASE KINASE 3BETA; HOMEODOMAIN PROTEIN; LEVODOPA; LITHIUM; LYSERGIDE; NEUROLEPTIC AGENT; PHENCYCLIDINE; PROTEIN KINASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TIANEPTINE; VALPROIC ACID; ZOLPIDEM;

ANXIETY; BIPOLAR DISORDER; BRAIN DEPTH STIMULATION; COMORBIDITY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISABILITY; DISEASE COURSE; DRUG EFFICACY; DRUG RESEARCH; DRUG TARGETING; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC ANALYSIS; HIGH THROUGHPUT SCREENING; HUMAN; MEDICAL SPECIALIST; MENTAL DISEASE; MOLECULAR BIOLOGY; NERVE CELL PLASTICITY; NEUROBIOLOGY; NEUROIMAGING; NEUROSCIENCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PATHOPHYSIOLOGY; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TRANSPORT; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SYMPOSIUM; TRANSCRANIAL MAGNETIC STIMULATION; VAGUS NERVE STIMULATION;

EID: 33847374225     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2217     Document Type: Review

References (78)

1. Manji, H. K., Gottesman, I.I. & Gould, T. D. Signal transduction and genes-to-behaviors pathways in psychiatric diseases. Sci. STKE 207, pe49 (2003).
2. Gould, T. D. & Gottesman, I. I. Psychiatric endophenotypes and the development of valid animal models. Genes Brain Behav. 5, 113-119 (2006).
3. Diagnostic and Statistical Manual of Mental Disorders 4th Edition (American Psychiatric Association, 2000).
4. Hasler, G., Gould, T. D., Drevets, W. C., Gottesman, I. I. & Manji, H. K. Toward constructing an endophenotype strategy for bipolar disorder. Biol. Psychiat. 60, 93-105 (2006).
5. Charney, D. S. & Manji, H. K. Life stress, genes and depression: multiple pathways lead to increased risk and new opportunities for intervention. Sci. STKE re5 (2004).
6. Einat, H. & Manji, H. K. Cellular plasticity cascades: Genes-to-behavior pathways in animal models of bipolar disorder. Biol. Psychiat. 59, 1160-1171 (2006).
7. Gould, T. D. & Manji, H. K. The molecular medicine revolution and psychiatry: Bridging the gap between basic neuroscience research and clinical psychiatry. J. Clin. Psychiat. 65, 598-604 (2004).
8. Berton, O. & Nestler, E. J. New approaches to antidepressant drug discovery: Beyond monoamines. Nature Rev. Neurosci. 7, 137-151 (2006).
9. Buzsaki, G. & Draguhn, A. Neuronal oscillations in cortical networks. Science 304, 1926-1929 (2004).
10. Robbe, D. et al. Cannabinoids reveal importance of spike timing coordination in hippocampal function. Nature Neurosci. 9,1526-1533 (2006).
11. Harris, K. D., Csicsvari, J., Hirase, H., Dragoi, G. & Buzsáki, G. Organization of cell assemblies in the hippocampus. Nature 424, 552-556 (2003).
12. Buzsaki, G. Large-scale recording of neuronal ensembles. Nature Neurosci. 7, 446-451 (2004).
13. Grace, A. A. The depolarization block hypothesis of neuroleptic action: implications for the etiology and treatment of schizophrenia. J. Neural Transm. Suppl. 36, 91-131 (1992).
14. Grace, A. A., Bunney, B. S., Moore, H. & Todd, C. L. Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci. 20, 31-37 (1997).
15. Rauch, S. L., Shin, L. M. & Phelps, E. A. Neurocircuitry models of posttraumatic stress disorder and extinction: Human neuroimaging research - past, present, and future. Biol. Psychiatry 60, 376-382 (2006).
16. McEwen, B. S. Glucocorticoids, depression, and mood disorders: structural remodeling in the brain. Metabolism 54 (Suppl. 1), 20-23 (2005).
17. Diamond, D. M., Campbell, A., Park, C. R. & Vouimba, R. M. Preclinical research on stress, memory, and the brain in the development of pharmacotherapy for depression. Eur. Neuropsychopharmacol. 14, S491-S495 (2004).
18. Bonanno, G. et al. Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J. Neurosci. 25, 3270-3279 (2005).
19. Grace, A. A. Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Res. Brain Res. Rev. 31, 330-341 (2000).
20. Weinberger, D. R. & Lipska, B. K. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: A search for common ground. Schizophr. Res. 16, 87-110 (1995).
21. Moore, H., Ghajarnia, M. E., Jentsch, J. D., Geyer, M. A. & Grace, A. A. A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: Implications for the neuropathology of schizophrenia. Biol. Psychiat. 60, 253-264 (2006).
22. Lipska, B. K. et al. Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology 122, 35-43 (1995).
23. Thompson, J. L., Pogue-Geile, M. F. & Grace, A. A. Developmental pathology, dopamine, and stress: A model for the age of onset of schizophrenia symptoms. Schizophr. Bull. 30, 875-900 (2004).
24. Grace, A. A. in Neurodevelopment and Schizophrenia (eds Keshavan, M., Kennedy, J. L. & Murray, R. M.) 273-294 (Cambridge Univ. Press, 2004).
25. Sugiyama, S., Dupas, S., Volovitch, M., Prochiantz, A. & Hensch, T. K. Endogenous Otx2 transfer into visual cortex specifies critical period plasticity. Ab. Soc. Neurosci. N25 A14 (2005).
26. Prakash, N. & Wurst, W. Development of dopaminergic neurons in the mammalian brain. Cell. Mol. Life Sci. 63, 187-206 (2006).
27. Joliot, A. & Prochiantz, A. Transduction peptides: From technology to physiology. Nature Cell Biol. 6, 189-196 (2004).
28. Somogyi, P. et al. Salient features of synaptic organisation in the cerebral cortex. Brain Res. Rev. 26, 113-135 (1998).
29. A receptor γ2 F771 point mutation. Eur. J. Neurosci. 21, 3002-3016 (2005).
30. A receptor subtype functions. Curr. Opinion Pharmacol. 6, 18-23 (2006).
31. A receptors: A viable target for novel anxiolytics? Curr. Opinion Pharmacol. 6, 24-29 (2006).
32. Calabresi, P. et al. Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity. J. Neurosci. 20, 8443-8451 (2000).
33. Greengard, P. The neurobiology of slow synaptic transmission. Science 294, 1024-1030 (2001).
34. Svenningsson, P. et al. DARPP-32 - an integrator of neurotransmission in the striatum. Ann. Rev. Pharmacol. Toxicol. 44, 269-296 (2004).
35. Svenningsson P. et al. Diverse psychotomimetics act through a common signaling pathway. Science 302, 1412-1415 (2003).
36. Valjent, E. et al. Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc. Natl Acad. Sci. USA 102, 491-496 (2005).
37. Valjent, E. et al. Plasticity-associated gene Krox24/Zif268 is required for long-lasting behavioral effects of cocaine. J. Neurosci. 26, 4956-4960 (2006).
38. Valjent, E. et al. Inhibition of ERK pathway or protein synthesis during reexposure to drugs of abuse erases previously learned place preference. Proc. Natl Acad. Sci. USA 103, 2932-2937 (2006).
39. Schenk, J. F. Safety of strong, static magnetic fields. J. Magn. Reson. Imaging 12, 2-19, (2000).
40. Thieben, M. J. et al. The distribution of structural neuropathology in pre-clinical Huntington's disease. Brain 125, 1815-1828 (2002).
41. Draganski, B. et al. Neuroplasticity: Changes in grey matter induced by training. Nature 427, 311-312 (2004).
42. Lee, L. et al. Acute remapping within the motor system induced by low-frequency repetitive transcranial magnetic stimulation. J. Neurosci. 23, 5308-5318, (2003).
43. Loubinoux, I. et al. A single dose of the serotonin neurotransmission agonist paroxetine enhances motor output: Double-blind, placebo-controlled, fMRI study in healthy subjects. Neuroimage 15, 26-36, (2002).
44. Giedd, J. N., Shaw, P., Wallace, G., Gogtay, N. & Lenroot, R. L. in Developmental Neuroscience Vol 2. 2nd edn (eds Cicchetti, D. & Cohen, D. J.) 127-196 (John Wiley & Sons, 2006).
45. Shaw, P. et al. Intellectual ability and cortical development in children and adolescents. Nature 440, 676-679 (2006).
46. Seckl J. R. & Meaney M. J. Glucocorticoid "programming" and PTSD risk. Ann. NY Acad. Sci. 1071, 351-378 (2006).
47. Olney, J. W. & Farber, N. B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 52, 998-1007 (1995).
48. Angrist, B. M. & Gershon, S. The phenomenology of experimentally induced amphetamine psychosis - preliminary observations. Biol. Psychiatry 2, 95-107 (1970).
49. Carlsson, A. & Lindqvist, M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol. 20, 140-144 (1963).
50. Creese, I., Burt, D. R. & Snyder, S. H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192, 481-483 (1976).
51. Flagstad, P. et al. Disruption of neurogenesis at gestational day 17 in the rat causes behavioral changes relevant to positive and negative schizophrenia symptoms and alters amphetamine-induced dopamine release in the nucleus accumbens. Neuropsychopharmacology 29, 2052-2064 (2004).
52. Gourevitch, R., Rocher, C., Le Pen, G., Krebs, M. O. & Jay, T. M. Working memory deficits in adult rats after prenatal disruption of neurogenesis. Behav. Pharmacol. 15, 287-292 (2004).
53. Grace, A. A. and Moore, H. in Origins and Development of Schizophrenia: Advances in Experimental Psychopathology (eds Lenzenweger, M. F. & Dworkin, R.H.) 123-157 (American Psychological Association Press, Washington DC, 1998).
54. Tsoory, M. & Richter-Levin, G. Learning under stress in the adult rat is differentially affected by or stress. Int. J. Neuropsychopharmacol. 2, 1-16 (2005).
55. Avital, A. & Richter-Levin, G. Exposure to juvenile stress exacerbates the behavioural consequences of exposure to stress in the adult rat. Int. J. Neuropsychopharmacol. 8, 163-173 (2005).
56. Cohen, H. et al. Setting apart the affected: The use of behavioral criteria in animal models of post traumatic stress disorder. Neuropsychopharmacology 29, 1962-1970 (2004).
57. Antman, E. H. et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; a report of ACC/AHA task force on practice guidelines. J. Am. Coll. Cardiol. 44, E1-E211 (2004).
58. Fitzgerald, P. B. et al. A randomized, controlled trial of sequential bilateral repetitive transcranial magnetic stimulation for treatment-resistant depression. Am. J. Psychiatry 163, 88-94 (2006).
59. Nahas, Z et al. Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J. Clin. Psychiatry 66,1097-1104 (2005).
60. Mayberg, H. S. et al. Deep brain stimulation for treatment resistant depression. Neuron 45, 651-660 (2005).
61. Mayberg, H. S. Modulating dysfunctional limbic-cortical circuits in depression: Towards development of brain-based algorithms for diagnosis and optimised treatment. Br. Med. Bull. 65,193-207 (2003).
62. Bertolino, A. et al. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am. J. Psychiatry 161, 1798-1805 (2004).
63. Weickert, T. W. et al. Catechol-O-methyltransferase val 108/158met genotype predicts working memory response to antipsychotic medications. Biol. Psychiatry 56, 677-682 (2004).
64. Grace, A. A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia. Neuroscience 41, 1-24 (1991).
65. Liddle, P. F., Friston, K. J., Frith, C. D. & Frachowiak, R. S. J., Cerebral blood flow and mental processes in schizophrenia. J. R. Soc. Med. 85, 224-227 (1992).
66. O'Donnell, P. & Grace, A. A. in Review of Psychiatry Vol 18: Schizophrenia in a Molecular Age. Ed. Tamminga, C. A. 109-140 (American Psychiatric Press, Washington DC, 1999).
67. Gould, T. & Manji, H. K. Glycogen synthase kinase-3: A putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 30, 1223-1237 (2005).
68. Diamond, D. M. et al. Influence of predator stress on the consolidation versus retrieval of long-term spatial memory and hippocampal spinogenesis. Hippocampus 16, 571-576 (2006).
69. Spedding, M., Jay, T., Costa e Silva. J. & Perret, L. A pathophysiological paradigm for the therapy of psychiatric disease. Nature Rev. Drug Discov. 4, 467-476 (2005).
70. Mayberg, H. S. et al. Reciprocal limbic-cortical function and negative converging PET findings in depression and normal sadness. Am. J. Psychiatry 156, 675-682 (1999).
71. Mayberg, H. S. et al. The functional neuroanatomy of the placebo effect. Am. J. Psychiatry 159, 728-737 (2002).
72. George, M. S. et al. Prefrontal repetitive transcranial magnetic stimulation (rTMS) reduces relative perfusion locally and remotely. Hum. Psychopharmacol. Clin. Exp. 14,161-170 (1999).
73. Nobler, M. S. et al. Decreased regional brain metabolism after ECT. Am. J. Psychiatry 158, 305-308 (2001).
74. Talbot, P. S. & Cooper, S. J. Anterior cingulate and subgenual prefrontal blood flow changes following tryptophan depletion in healthy males. Neuropsychopharmacology 31,1757-1767 (2006).
75. Pezawas, L. et al. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: A genetic susceptibility mechanism for depression. Nature Neurosci. 8, 828-834 (2005).
76. Ongur, D., Drevet, W. C. & Price, J. L. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc. Natl Acad. Sci. USA 95, 13290-13295 (1998).
77. Somogyi, P. & Klausberger, T. Defined types of cortical interneurone structure space and spike timing in the hippocampus. J. Physiol. 562, 9-26 (2005).
78. Ohyama, A. et al. Regulation of exocytosis through Ca2/ATP-dependent binding of autophosphorylated Ca2/calmodulin-activated protein kinase II to syntaxin1A. J. Neurosci. 22, 3342-3351 (2002).